Literature DB >> 27916044

[A cross-section study of severe asthma in eight provinces of China].

N Su, J T Lin1, W Y Wang, P Chen, X Zhou, H Y Wan, K S Yin, L J Ma, C G Wu, J Li, C T Liu, Y M Zhang, G L Liu, H Xie, W Tang, M Huang, Y Chen, Y H Liu, L Q Song, X L Chen.   

Abstract

Objective: To analyze the prevalence of severe asthmain China.
Methods: The epidemiological data was collected from 2 034 asthmatics who were diagnosed in the last epidemiological survey from 2009 to 2010 in 8 provinces.
Results: According to the questionnaire survey, among the 2 034 patients, the previously diagnosed patients accounted for 72.47% (1 474/2 034) and the percentage of newly-diagnosed patients was 27.53% (560/2 034). In those 1 474 previously diagnosed asthmatics, 122 (8.28%) were classified into severe asthma, while 6.00% (122/2 034) of all asthmatics and 0.07% (122/164 215) of total respondents presented as severe cases. Statistically, there was no difference in the prevalence of severe patients between men and women. The morbidity rate of severe asthma was the lowest in the 21-30 year old group and the highest in 61-70 year old group (0.85% and 8.31% respectively). The difference among ages was statistically significant (χ2=18.791, P=0.005). In addition, the prevalence rates of severe asthma were also significantly diverged among patients with different education background(χ2=24.639, P<0.000 1). A negative relation was found between education level and the proportion of severe cases. Moreover, the morbidity of severe asthma in smoking patients and non-smoking patients were significantly different as well (χ2=7.447, P<0.05). Compared with asthma patients who do not smoke, smokers were more likely to suffer severe asthma (OR=1.663, 95% CI 1.150-2.404). Conclusions: The prevalence rate of severe asthma in China is similar to that in other countries.Elderly patients have higher risk of severe asthma. Smoking is considered as a risk factor for severe asthma.

Entities:  

Mesh:

Year:  2016        PMID: 27916044     DOI: 10.3760/cma.j.issn.0578-1426.2016.12.002

Source DB:  PubMed          Journal:  Zhonghua Nei Ke Za Zhi        ISSN: 0578-1426


  3 in total

1.  Efficacy predictors of omalizumab in Chinese patients with moderate-to-severe allergic asthma: Findings from a post-hoc analysis of a randomised phase III study.

Authors:  Jing Li; Changzheng Wang; Chuntao Liu; Jian Kang; Lingfei Kong; Yijiang Huang; Shuang Liu; Mao Huang; Lu Wang; Robert Fogel; Xavier Jaumont; Jing Yang; Nanshan Zhong
Journal:  World Allergy Organ J       Date:  2020-11-24       Impact factor: 4.084

2.  Severe eosinophilic asthma in Chinese C-BIOPRED asthma cohort.

Authors:  Qingling Zhang; Xiuhua Fu; Changzheng Wang; Huahao Shen; Lei Zhu; Guochao Shi; Zhongmin Qiu; Zhongguang Wen; Wei Gu; Wei Luo; Lina Zhao; Yunqin Chen; Sam Lim; Chang Xiao; Jian Kang; Yunhui Zhang; Mao Huang; Jinfu Xu; Kewu Huang; Qiang Li; Xiangyan Zhang; Jianping Zhao; Xiaoxia Liu; Shenghua Sun; Huaping Tang; Bei He; Shaoxi Cai; Ping Chen; Chunhua Wei; Guangfa Wang; Ping Chen; Lixin Xie; Jiangtao Lin; Yuling Tang; Zhihai Han; Kian Fan Chung; Nanshan Zhong
Journal:  Clin Transl Med       Date:  2022-02

3.  Newly diagnosed asthma in China: initial severity and changes over a 1-year management period.

Authors:  Zhizhen Hu; Jianwei Xuan; Haijin Zhao; Hangming Dong; Changhui Yu; Shaoxi Cai; Yue Gao; Liran Li; Xiaohan Hu
Journal:  Ann Transl Med       Date:  2022-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.